Clinical Research Directory
Browse clinical research sites, groups, and studies.
MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies
Sponsor: Medical University of Warsaw
Summary
The goal of this study is to evaluate the effectiveness of trametinib treatment in patients with Hyperthropic cardiomyopathy and a genetic mutation in the RAS/MAPK pathway.
Official title: MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies (MEKinRAS) - Randomized Controlled Trial
Key Details
Gender
All
Age Range
1 Day - 18 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-08-01
Completion Date
2026-12-01
Last Updated
2024-08-15
Healthy Volunteers
No
Conditions
Interventions
Trametinib tablet
Trametynib orally once daily in 0,025mg/kg dose
Standard therapy
Disopiramide and Beta blockers orally
Locations (1)
Department of Paediatrics, The Medical University of Warsaw, Poland
Warsaw, Poland